<table>
<thead>
<tr>
<th>Full Name</th>
<th>HCPs: City of Principal Practice</th>
<th>HCOs: city where registered</th>
<th>Country of Principal Practice</th>
<th>Principal Practice Address</th>
<th>Unique country identifier OPTIONAL</th>
<th>Donations and Grants to HCOs</th>
<th>Contribution to costs of Events (Art 3.01.1 &amp; 3.01.2)</th>
<th>Fee for service and consultancy (Art 3.01.1 &amp; 3.01.2)</th>
<th>TOTAL (EUR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob, Lynn</td>
<td>Luxembourg</td>
<td>Luxembourg</td>
<td>4 Rue Nicolas Ernest Barblé</td>
<td>200.00</td>
<td>-</td>
<td>-</td>
<td>Related expenses agreed in the fee for service or consultancy contract, including travel &amp; accommodation relevant to contract</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDIVIDUAL NAMED DISCLOSURE**—one line per HCO(i.e. all transfers of value during a year for an individual HCO will be summed up (transparency should be available for the individual Recipient or public authorities, consultation only, as appropriate)

**OTHER, NOT INCLUDED ABOVE**—information cannot be disclosed on an individual basis for legal reasons

Aggregate amount attributable to transfers of value to such Recipients - Art 3.02
Number of Recipients in aggregate disclosure - Art 3.02
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02

**INDIVIDUAL NAMED DISCLOSURE**—one line per HCP(i.e. all transfers of value during a year for an individual HCP will be summed up (transparency should be available for the individual Recipient or public authorities consultation only, as appropriate)

**OTHER, NOT INCLUDED ABOVE**—information cannot be disclosed on an individual basis for legal reasons

Aggregate amount attributable to transfers of value to such Recipients - Art 3.02
Number of Recipients in aggregate disclosure - Art 3.02
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02

**AGGREGATE DISCLOSURE**

Transfers of Value re Research & Development as defined - Article 3.04 and schedule 1